“Shift from Plasma-Derived to Recombinant C1-INH Products”
Recombinant C1-INH therapies are gaining traction due to their potential for higher purity and consistency compared to plasma-derived alternatives. Recombinant therapies also carry a lower risk of bloodborne pathogen transmission, which is a significant concern for plasma-based products. This shift is influencing the market as patients and healthcare providers opt for the safety and reliability of recombinant therapies. Leading companies are focusing on the development and commercialization of recombinant C1-INH products, which are seen as the future of treatment for hereditary angioedema and other complement-related disorders.
